drugset / Trial / NCT06930651
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the recommended safe dose of TGFBR2 KO CAR27/IL-15 NK cells that can be given to patients with relapsed/refractory disease. The safety and effectiveness of this treatment will also be studied.
Timeline
- Start
- 2025-09-03
- Primary completion
- 2028-05-01
- Completion
- 2030-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TGFBR2 KO CAR27/IL-15 NK cells | Cell therapy | — | Other |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Decitabine | Small molecule | — | Intravenous |
| Background | Dexamethasone | Small molecule | — | Oral |
| Background | Fludarabine | Small molecule | — | Intravenous |